Cargando…
Severe Epistaxis after Tissue Plasminogen Activator administration for Acute Ischemic Stroke in SARS-COV-2 Infection
Patients with COVID-19 may suffer from hemorrhagic complications. Our article highlights two cases of COVID-19-infected patients, who suffered severe epistaxis after initiation of intravenous recombinant tissue plasminogen activator (IV-rtPA) for acute ischemic stroke, followed by a sudden decline i...
Autores principales: | Khandelwal, Priyank, Martínez-Pías, Enrique, Bach, Ivo, Prakash, Tannavi, Hillen, Machteld E., Martínez-Galdámez, Mario, Arenillas, Juan F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191532/ https://www.ncbi.nlm.nih.gov/pubmed/34189359 http://dx.doi.org/10.4103/bc.bc_17_21 |
Ejemplares similares
-
Incidence, Pathophysiology, and Impact of Coronavirus Disease 2019 (COVID-19) on Acute Ischemic Stroke
por: Majmundar, Neil, et al.
Publicado: (2020) -
Stroke in COVID-19: a single-centre initial experience in a hotspot of the pandemic
por: Bach, Ivo, et al.
Publicado: (2020) -
Association of Geographical Factors With Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Kunisawa, Susumu, et al.
Publicado: (2013) -
Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke
por: Chaucer, Benjamin, et al.
Publicado: (2018) -
Treatment of Epistaxis by Internal Administration of Ergot
Publicado: (1876)